
Related articles


Part 2: Restoring the American Biotechnology Edge
Most of a clinical trial's budget pays for coordination, not science. Michelle Longmire, MD, shows how supervised agentic AI can take on that work, reaching the same milestone with about 42% less capital and far less waiting time.


Part 1: Restoring the American Biotechnology Edge
American biotechnology still leads in scientific innovation, but its advantage in turning science into medicine is eroding. Part 1 examines how slower, more expensive clinical development is shifting the competitive edge toward China, and what’s at stake for the future of U.S. biotech.


The age of agentic A complete guide on agents in clinical trials
A complete guide to AI agents in clinical trials, includingwhat they are, the infrastructure they need, where people stay in charge, and how to start. Discover how agentic AI is transforming clinical trials, and what's next. And, learn about ontologies, human-in-the-loop governance, build vs. buy, continuous validation/governance, and more.



